Literature DB >> 19116631

ESCGT 2008: progress in clinical gene therapy.

David A Williams.   

Abstract

Mesh：

Year:  2009        PMID： 19116631      PMCID： PMC2834979          DOI： 10.1038/mt.2008.277

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  3 in total

1.  Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.

Authors:  Gerd J Bauerschmitz; Kilian Guse; Anna Kanerva; Artur Menzel; Isabell Herrmann; Renee A Desmond; Masato Yamamoto; Dirk M Nettelbeck; Tanja Hakkarainen; Peter Dall; David T Curiel; Akseli Hemminki
Journal:  Mol Ther       Date:  2006-03-31       Impact factor: 11.454

2.  AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.

Authors:  Arto Immonen; Matti Vapalahti; Kristiina Tyynelä; Heleena Hurskainen; Anu Sandmair; Ritva Vanninen; Gillian Langford; Neil Murray; Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

3.  Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.

Authors:  Minna Eriksson; Kilian Guse; Gerd Bauerschmitz; Pekka Virkkunen; Maija Tarkkanen; Minna Tanner; Tanja Hakkarainen; Anna Kanerva; Renee A Desmond; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2007-09-11       Impact factor: 11.454
  3 in total
  1 in total

1.  A new technique of ex vivo gene delivery of VEGF to wounds using genetically modified skin particles promotes wound angiogenesis.

Authors:  Taro Koyama; Florian Hackl; Pejman Aflaki; Juri Bergmann; Baraa Zuhaili; Emily Waisbren; Usha Govindarajulu; Feng Yao; Elof Eriksson
Journal:  J Am Coll Surg       Date:  2011-01-17       Impact factor: 6.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.